From 31 January 2022 there will be a new vaccine available, Vaxelis® as an alternative to Infanrix hexa® (DTap/IPV/Hib/HepB). There will be no change to the ordering process.

Both vaccines are interchangeable, however where possible, it is preferable that the same vaccine is used for all three doses of the routine primary immunisations scheduled at 8, 12 and 16 weeks of age. Vaccination should not be delayed if the vaccine used previously is not available or unknown. 

Use of both Vaxelis® and Infanrix hexa® is included in the hexavalent vaccine DTaP/IPV/Hib/HepB PGD national template, version 03.00 and further details can be found in the Vaxelis® Summary of Product Characteristics. Further information regarding training and updated information for HCP’s will be available in due course.